[go: up one dir, main page]

WO2024129897A3 - Anticorps anti-cd3 et anticorps bispécifiques - Google Patents

Anticorps anti-cd3 et anticorps bispécifiques Download PDF

Info

Publication number
WO2024129897A3
WO2024129897A3 PCT/US2023/083893 US2023083893W WO2024129897A3 WO 2024129897 A3 WO2024129897 A3 WO 2024129897A3 US 2023083893 W US2023083893 W US 2023083893W WO 2024129897 A3 WO2024129897 A3 WO 2024129897A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
bispecific
bispecific antibodies
tumor antigen
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/083893
Other languages
English (en)
Other versions
WO2024129897A2 (fr
Inventor
Zhong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bj Bioscience Inc
Original Assignee
Bj Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bj Bioscience Inc filed Critical Bj Bioscience Inc
Publication of WO2024129897A2 publication Critical patent/WO2024129897A2/fr
Publication of WO2024129897A3 publication Critical patent/WO2024129897A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

On a découvert que certains formats d'anticorps bispécifiques qui ciblent à la fois CD3 et un antigène tumoral ont un indice thérapeutique considérablement amélioré par rapport aux anticorps classiques. De tels anticorps bispécifiques comprennent une partie anti-CD3 classique fusionnée à quatre anticorps à domaine unique ciblant l'antigène tumoral. Dans certains scénarios, les bras de liaison peptidiques utilisés pour relier les parties ont une longueur appropriée qui permet une puissance de destruction tumorale maximisée mais avec des activités de libération de cytokine réduites. L'invention concerne également de nouveaux anticorps et fragments ciblant CD3, CD38 et FOLR1.
PCT/US2023/083893 2022-12-13 2023-12-13 Anticorps anti-cd3 et anticorps bispécifiques Ceased WO2024129897A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263432248P 2022-12-13 2022-12-13
US63/432,248 2022-12-13

Publications (2)

Publication Number Publication Date
WO2024129897A2 WO2024129897A2 (fr) 2024-06-20
WO2024129897A3 true WO2024129897A3 (fr) 2024-08-29

Family

ID=91485844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/083893 Ceased WO2024129897A2 (fr) 2022-12-13 2023-12-13 Anticorps anti-cd3 et anticorps bispécifiques

Country Status (1)

Country Link
WO (1) WO2024129897A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080305105A1 (en) * 2003-12-22 2008-12-11 Peter Kufer Bispecific antibodies
US20110053865A1 (en) * 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2018199593A1 (fr) * 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Anticorps bispécifique se liant à her3 et cd3
WO2022150792A1 (fr) * 2021-01-11 2022-07-14 Soteria Biotherapeutics, Inc. Compositions d'engagement de lymphocytes t de dimérisation chimique à base d'indinavir

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080305105A1 (en) * 2003-12-22 2008-12-11 Peter Kufer Bispecific antibodies
US20110053865A1 (en) * 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2018199593A1 (fr) * 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Anticorps bispécifique se liant à her3 et cd3
WO2022150792A1 (fr) * 2021-01-11 2022-07-14 Soteria Biotherapeutics, Inc. Compositions d'engagement de lymphocytes t de dimérisation chimique à base d'indinavir

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARMSEN ET AL.: "Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin", VETERINARY MICROBIOLOGY, vol. 132, 2008, pages 56 - 64, XP025431266, DOI: 10.1016/j.vetmic.2008.04.030 *

Also Published As

Publication number Publication date
WO2024129897A2 (fr) 2024-06-20

Similar Documents

Publication Publication Date Title
AU2021201003B2 (en) Trispecific binding proteins and methods of use
Hammill et al. Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Schmohl et al. Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells
Schmohl et al. Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity
ES2203141T3 (es) Polipeptidos cd19 x cd3 especificos y su utilizacion.
CA2148712A1 (fr) Peripherisation de cellules souches hematopoietiques
RU2203319C2 (ru) Биспецифическая молекула антитела для лизиса опухолевых клеток, способ получения f(ab') 2 фрагмента биспецифической молекулы антитела, моноклональное антитело (варианты), фармацевтический препарат, фармацевтический набор для лизиса опухолевых клеток (варианты), способ лизиса опухолевых клеток ex vivo при аутогенной трансплантации костного мозга
TWI676681B (zh) 具抗原專一性的t細胞及其用途
Hombach et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo
JP2020015760A (ja) キメラ抗原受容体ｔ細胞スイッチおよびその使用
JP3592711B2 (ja) 細胞毒性剤治療
CN102250245B (zh) 抗b细胞淋巴瘤的双特异性抗体及其用途
AU2011373925A1 (en) Multivalent antigen-binding Fv molecule
JPH06501705A (ja) 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
Hidalgo et al. Switchable CAR T cell strategy against osteosarcoma
WO2024102693A3 (fr) Protéines de fusion il-18-fc
Guo et al. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity
WO2023015170A3 (fr) Anticorps anti-cd38, anticorps anti-cd3 et anticorps bispécifiques, et leurs utilisations
ZA202305642B (en) Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
WO2024129897A3 (fr) Anticorps anti-cd3 et anticorps bispécifiques
CN108602886A (zh) 用于在癌症免疫疗法中使用的双特异性抗体
Ren‐Heidenreich et al. Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model
Bakács et al. A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma
Lu et al. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V
Somasundaram et al. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23904534

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23904534

Country of ref document: EP

Kind code of ref document: A2